Cargando…

Efficacy and tolerability of low-dose oral prolonged-release oxycodone/naloxone for chronic nononcological pain in older patients

PURPOSE: Chronic pain is highly prevalent in older adults. Increasing evidence indicates strong opioids as a valid option for chronic pain management in geriatrics. The aim of this study was to evaluate efficacy and safety of low-dose oral prolonged-release oxycodone–naloxone (OXN-PR) in patients ag...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guerriero, Fabio, Sgarlata, Carmelo, Marcassa, Claudio, Ricevuti, Giovanni, Rollone, Marco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4279666/ https://www.ncbi.nlm.nih.gov/pubmed/25565782 http://dx.doi.org/10.2147/CIA.S72521

Ejemplares similares

Is oxycodone/naloxone effective and safe in managing chronic pain of a fragile elderly patient with multiple skin ulcers of the lower limbs? A case report
por: Guerriero, Fabio, et al.
Publicado: (2015)

Long-term efficacy and safety of oxycodone–naloxone prolonged release in geriatric patients with moderate-to-severe chronic noncancer pain: a 52-week open-label extension phase study
por: Guerriero, Fabio, et al.
Publicado: (2016)

Low-dose oral prolonged-release oxycodone/naloxone for chronic pain in elderly patients with cognitive impairment: an efficacy–tolerability pilot study
por: Petrò, Emiliano, et al.
Publicado: (2016)

Efficacy and tolerability of oral oxycodone and oxycodone/naloxone combination in opioid-naïve cancer patients: a propensity analysis
por: Lazzari, Marzia, et al.
Publicado: (2015)

Switching to low-dose oral prolonged-release oxycodone/naloxone from WHO-Step I drugs in elderly patients with chronic pain at high risk of early opioid discontinuation
por: Lazzari, Marzia, et al.
Publicado: (2016)

Pain therapy with oxycodone/naloxone prolonged-release combination: case report
por: Błaszczyk, Feliks, et al.
Publicado: (2013)

Intractable restless legs syndrome: role of prolonged-release oxycodone–naloxone
por: de Biase, Stefano, et al.
Publicado: (2016)

Analgesic effectiveness and tolerability of oral oxycodone/naloxone and pregabalin in patients with lung cancer and neuropathic pain: an observational analysis
por: De Santis, Stefano, et al.
Publicado: (2016)

Colorectal Transit and Volume During Treatment With Prolonged-release Oxycodone/Naloxone Versus Oxycodone Plus Macrogol 3350
por: Poulsen, Jakob L, et al.
Publicado: (2018)

Methodological Issues on a Clinical Trial to Test Tapentadol Prolonged release vs. Oxycodone/Naloxone Prolonged release
por: Bacallao, Jorge, et al.
Publicado: (2016)

Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain
por: Sandner-Kiesling, A, et al.
Publicado: (2010)

Analgesic Efficacy and Safety of Prolonged-Release Oxycodone/Naloxone in Korean Patients with Chronic Pain from Spinal Disorders
por: Hwang, Chang Ju, et al.
Publicado: (2018)

Long-term safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe chronic cancer pain
por: Ahmedzai, Sam H., et al.
Publicado: (2014)

Developments in managing severe chronic pain: role of oxycodone–naloxone extended release
por: Fanelli, Guido, et al.
Publicado: (2015)

Cancer pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: results from a non-interventional study
por: Nolte, Thomas, et al.
Publicado: (2013)

The place of oxycodone/naloxone in chronic pain management
por: Leppert, Wojciech
Publicado: (2013)

ENhANCE trial protocol: A multi-centre, randomised, phase IV trial comparing the efficacy of oxycodone/naloxone prolonged release (OXN PR) versus oxycodone prolonged release (Oxy PR) tablets in patients with advanced cancer
por: Wong, Aaron K., et al.
Publicado: (2022)

An innovative intervention for the treatment of cognitive impairment–Emisymmetric bilateral stimulation improves cognitive functions in Alzheimer’s disease and mild cognitive impairment: an open-label study
por: Guerriero, Fabio, et al.
Publicado: (2015)

A phase III randomized controlled study on the efficacy and improved bowel function of prolonged‐release (PR) oxycodone‐naloxone (up to 160/80 mg daily) vs oxycodone PR
por: Dupoiron, D., et al.
Publicado: (2017)

Prolonged-release oxycodone/naloxone reduces opioid-induced constipation and improves quality of life in laxative-refractory patients: results of an observational study
por: Bantel, Carsten, et al.
Publicado: (2018)

Efficacy and safety of controlled-release oxycodone/naloxone versus controlled-release oxycodone in Korean patients with cancer-related pain: a randomized controlled trial
por: Lee, Kyung-Hee, et al.
Publicado: (2017)

Prolonged-Release (PR) Oxycodone/Naloxone Improves Bowel Function Compared with Oxycodone PR and Provides Effective Analgesia in Chinese Patients with Non-malignant Pain: A Randomized, Double-Blind Trial
por: Leng, Xiaomei, et al.
Publicado: (2020)

Effectiveness of an Innovative Pulsed Electromagnetic Fields Stimulation in Healing of Untreatable Skin Ulcers in the Frail Elderly: Two Case Reports
por: Guerriero, Fabio, et al.
Publicado: (2015)

Opioid-Induced Bowel Dysfunction in Patients Undergoing Spine Surgery: Comparison of Oxycodone and Oxycodone-Naloxone Treatment
por: Kokki, Merja, et al.
Publicado: (2016)

Treatment of Opioid Withdrawal Syndrome Triggered by Oxycodone/Naloxone with Dexmedetomidine
por: Go, Se-Il, et al.
Publicado: (2023)

A comparison between the administration of oral prolonged-release oxycodone-naloxone and transdermal fentanyl in patients with moderate-to-severe cancer pain: a propensity score analysis
por: Roberto, A, et al.
Publicado: (2017)

Combatting pain after orthopedic/trauma surgery- perioperative oral extended-release tapentadol vs. extended-release oxycodone/naloxone
por: Haeseler, Gertrud, et al.
Publicado: (2017)

PET/CT in nononcological lung diseases: current applications and future perspectives
por: Capitanio, Selene, et al.
Publicado: (2016)

Quality of life under oxycodone/naloxone, oxycodone, or morphine treatment for chronic low back pain in routine clinical practice
por: Ueberall, Michael A, et al.
Publicado: (2016)

Long-term evaluation of combined prolonged-release oxycodone and naloxone in patients with moderate-to-severe chronic pain: pooled analysis of extension phases of two Phase III trials
por: Blagden, M, et al.
Publicado: (2014)

Abuse Potential of Intravenous Oxycodone/Naloxone Solution in Nondependent Recreational Drug Users
por: Colucci, Salvatore V., et al.
Publicado: (2014)

Combined Administration of Oxycodone/Naloxone in Chronic Osteo-Articular Diseases Pain Therapy
por: Rosa, Palomba, et al.
Publicado: (2014)

Histopathological Audit of 373 Nononcological Hysterectomies in a Teaching Hospital
por: Tiwana, Kanwardeep Kaur, et al.
Publicado: (2014)

Pain treatment with high-dose, controlled-release oxycodone: an Italian perspective
por: Ferrarese, Fabio, et al.
Publicado: (2008)

Treatment of Failed Back Surgery Syndrome in a Forty-Three-Year-Old Man With High-Dose Oxycodone/Naloxone
por: Bujedo, Borja Mugabure
Publicado: (2015)

Oxycodone/Naloxone: Role in Chronic Pain Management, Opioid-Induced Constipation, and Abuse Deterrence
por: DePriest, Anne Z., et al.
Publicado: (2014)

Assessment of Neurotoxic Effects of Oxycodone and Naloxone in SH-SY5Y Cell Line
por: Lima, Luíza Siqueira, et al.
Publicado: (2023)

Long‐term efficacy and safety of oxycodone‐naloxone prolonged‐release formulation (up to 180/90 mg daily) – results of the open‐label extension phase of a phase III multicenter, multiple‐dose, randomized, controlled study
por: Dupoiron, D., et al.
Publicado: (2017)

Low-dose modified-release prednisone in axial spondyloarthritis: 3-month efficacy and tolerability
por: Bandinelli, Francesca, et al.
Publicado: (2016)

Do Value Thresholds for Oncology Drugs Differ from Nononcology Drugs?
por: Bae, Yuna Hyo Jung, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_2kcv85h5c59d9fo7svpcgab7oi